DE69230220D1 - Substituierte guanidine und derivate hiervon als modulatoren der freisetzung von neurotransmittern und neue methode zur identifizierung von inhibitoren der neurotransmitter-freisetzung - Google Patents

Substituierte guanidine und derivate hiervon als modulatoren der freisetzung von neurotransmittern und neue methode zur identifizierung von inhibitoren der neurotransmitter-freisetzung

Info

Publication number
DE69230220D1
DE69230220D1 DE69230220T DE69230220T DE69230220D1 DE 69230220 D1 DE69230220 D1 DE 69230220D1 DE 69230220 T DE69230220 T DE 69230220T DE 69230220 T DE69230220 T DE 69230220T DE 69230220 D1 DE69230220 D1 DE 69230220D1
Authority
DE
Germany
Prior art keywords
release
modulators
disclosed
neurotransmitters
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69230220T
Other languages
English (en)
Other versions
DE69230220T2 (de
Inventor
Stanley Goldin
Subbarao Katragadda
Lain-Yen Hu
N Reddy
James Fischer
Andrew Knapp
Lee Margolin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Neuroscience Research Inc
Original Assignee
Cambridge Neuroscience Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Neuroscience Research Inc filed Critical Cambridge Neuroscience Research Inc
Application granted granted Critical
Publication of DE69230220D1 publication Critical patent/DE69230220D1/de
Publication of DE69230220T2 publication Critical patent/DE69230220T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/16—Compounds containing any of the groups, e.g. aminoguanidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/16—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/20—Acenaphthenes; Hydrogenated acenaphthenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE69230220T 1991-02-08 1992-02-10 Substituierte guanidine und derivate hiervon als modulatoren der freisetzung von neurotransmittern und neue methode zur identifizierung von inhibitoren der neurotransmitter-freisetzung Expired - Fee Related DE69230220T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65210491A 1991-02-08 1991-02-08
PCT/US1992/001050 WO1992014697A1 (en) 1991-02-08 1992-02-10 Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers

Publications (2)

Publication Number Publication Date
DE69230220D1 true DE69230220D1 (de) 1999-12-02
DE69230220T2 DE69230220T2 (de) 2000-06-21

Family

ID=24615532

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69233479T Expired - Fee Related DE69233479T2 (de) 1991-02-08 1992-02-10 Substituierte Guanidine und Derivate hiervon als Modulatoren der Freisetzung von Neurotransmittern und neue Methode zur Identifizierung von Inhibitoren der Neurotransmitter-Freisetzung
DE69230220T Expired - Fee Related DE69230220T2 (de) 1991-02-08 1992-02-10 Substituierte guanidine und derivate hiervon als modulatoren der freisetzung von neurotransmittern und neue methode zur identifizierung von inhibitoren der neurotransmitter-freisetzung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69233479T Expired - Fee Related DE69233479T2 (de) 1991-02-08 1992-02-10 Substituierte Guanidine und Derivate hiervon als Modulatoren der Freisetzung von Neurotransmittern und neue Methode zur Identifizierung von Inhibitoren der Neurotransmitter-Freisetzung

Country Status (12)

Country Link
US (12) US5403861A (de)
EP (2) EP0584088B1 (de)
JP (1) JPH06506455A (de)
KR (1) KR100246083B1 (de)
AT (2) ATE186047T1 (de)
AU (2) AU670232B2 (de)
CA (1) CA2099245A1 (de)
DE (2) DE69233479T2 (de)
IE (2) IE20030530A1 (de)
PT (1) PT100115B (de)
WO (1) WO1992014697A1 (de)
ZA (1) ZA92944B (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733933A (en) * 1984-03-19 1998-03-31 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5312840A (en) * 1986-07-10 1994-05-17 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education Substituted guanidines having high binding to the sigma receptor and the use thereof
US5385946A (en) * 1986-07-10 1995-01-31 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Method for treating hypertension with disubstituted granidine compounds
US5871472A (en) * 1987-11-17 1999-02-16 Brown University Research Foundation Planting devices for the focal release of neuroinhibitory compounds
US5336689A (en) * 1990-03-02 1994-08-09 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists
US5262568A (en) * 1990-03-02 1993-11-16 State Of Oregon Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists
KR100353486B1 (ko) * 1990-03-02 2003-01-06 스테이트 오브 오레곤,액팅 바이 앤드 쓰로우 디 오레곤 스테이트 보드 오브 하이어 에주케이션,액팅포앤드 온 비해프 오브 디 오레곤 헬쓰 사이언시즈 유니버시티 앤드 더 유니버시티 오브 오레곤,유진,오레곤 삼치환및사치환된구아니딘류및이를함유하는약제조성물
AU670232B2 (en) * 1991-02-08 1996-07-11 Cambridge Neuroscience, Inc. Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers
US5741661A (en) * 1991-02-08 1998-04-21 Cambridge Neuroscience, Inc. Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers
US5847006A (en) * 1991-02-08 1998-12-08 Cambridge Neuroscience, Inc. Therapeutic guanidines
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6673335B1 (en) * 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
JP3717925B2 (ja) * 1992-09-29 2005-11-16 ネクター セラピューティクス 副甲状腺ホルモンの活性フラグメントの肺導入
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
CN1188121C (zh) * 1993-05-27 2005-02-09 剑桥神经科学公司 治疗性取代的胍类
CA2177084A1 (en) * 1993-11-22 1995-06-01 Sharad Magar Therapeutic guanidines
JPH09505591A (ja) * 1993-11-23 1997-06-03 ケンブリッジ・ニューロサイエンス・インコーポレーテッド 治療用置換グアニジン類
WO1995020950A1 (en) * 1994-02-03 1995-08-10 Cambridge Neuroscience, Inc. Therapeutic guanidines
US6410598B1 (en) 1994-02-03 2002-06-25 Michael P. Vitek Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
US7351743B1 (en) 1994-02-03 2008-04-01 Wyeth Therapeutic guanidines
US6143791A (en) * 1994-02-03 2000-11-07 Cambridge Neuroscience, Inc. Therapeutic guanidines
US6787569B1 (en) 1994-02-03 2004-09-07 Cambridge Neuroscience, Inc. Therapeutic guanidines
WO1995020979A1 (en) * 1994-02-03 1995-08-10 The Picower Institute For Medical Research Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
US5897858A (en) 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
AU1882395A (en) * 1994-02-23 1995-09-11 Cambridge Neuroscience, Inc. Blockers of ion channels and methods of use thereof
US20030113273A1 (en) * 1996-06-17 2003-06-19 Patton John S. Methods and compositions for pulmonary delivery of insulin
WO1995024183A1 (en) * 1994-03-07 1995-09-14 Inhale Therapeutic Systems Methods and compositions for pulmonary delivery of insulin
GB2288732B (en) * 1994-04-13 1998-04-29 Quadrant Holdings Cambridge Pharmaceutical compositions
EP0759939B1 (de) * 1994-05-18 2005-07-20 Nektar Therapeutics Methoden und zusammensetzungen für die trockenpuderarznei aus interferonen
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
KR100293621B1 (ko) 1994-10-21 2001-11-26 젠센, 제임스 유. 칼슘수용체-활성화합물
AU4151996A (en) * 1994-11-08 1996-05-31 Avicena Group, Inc. Use of creatine or creatine analogs for the treatment of diseases of the nervous system
US6025355A (en) 1997-05-19 2000-02-15 Cambridge Neuroscience, Inc. Pharmaceutically active compounds and methods of use
ES2201300T3 (es) * 1996-05-01 2004-03-16 Nps Pharmaceuticals, Inc. Compuestos activos frente a receptores de iones inorganicos.
US5824662A (en) * 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US6242198B1 (en) 1996-07-25 2001-06-05 Cambridge Neuroscience, Inc. Methods of treatment of eye trauma and disorders
US6756389B2 (en) * 1996-08-09 2004-06-29 Cambridge Neuroscience, Inc. Pharmaceutically active compounds and methods of use
US5780489A (en) * 1996-08-21 1998-07-14 Brooks; Benjamin Rix Method for treating amyotrophic lateral sclerosis
PL332413A1 (en) 1996-09-27 1999-09-13 Guilford Pharm Inc Compositions containing inhibitors of naaladase as well as methods of treating glutamatic anomaly and influencing neuronic functions among animals
US6143728A (en) * 1996-11-15 2000-11-07 The Picower Institute For Medical Research Guanylhydrazones useful for treating diseases associated with T cell activation
WO1998036743A1 (en) * 1997-02-21 1998-08-27 Cypros Pharmaceutical Corporation Neuroprotective poly-guanidino compounds which block presynaptic n and p/q calcium channels
AU8278498A (en) * 1997-07-07 1999-02-08 Cambridge Neuroscience, Inc. Combination drug therapies comprising aminoglycoside antibiotics and n,n'-disubstituted guanidines
US20030035778A1 (en) * 1997-07-14 2003-02-20 Robert Platz Methods and compositions for the dry powder formulation of interferon
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6774263B1 (en) 1997-10-10 2004-08-10 Cambridge Neuroscience, Inc. Pharmaceutically active compound and methods of use
JP2002510604A (ja) * 1998-04-02 2002-04-09 アビセナ グループ， インク． クレアチン化合物及び第二物質の組み合わせを含む組成
US20060128671A1 (en) * 1998-04-02 2006-06-15 The General Hospital Corporation Compositions containing a combination of a creatine compound and a second agent
US6462034B1 (en) 1998-04-03 2002-10-08 Theravance, Inc. Local anesthetic compounds and uses
PE20000354A1 (es) 1998-04-03 2000-05-20 Advanced Medicine Inc Nuevos compuestos y usos anestesicos locales
US6268398B1 (en) 1998-04-24 2001-07-31 Mitokor Compounds and methods for treating mitochondria-associated diseases
EP1089749A4 (de) * 1998-06-08 2001-04-11 Advanced Medicine Inc Therapeutische mittel für den membrantransport
US6897305B2 (en) 1998-06-08 2005-05-24 Theravance, Inc. Calcium channel drugs and uses
US6420354B1 (en) 1998-06-08 2002-07-16 Advanced Medicine, Inc. Sodium channel drugs and uses
US7101909B2 (en) * 1998-10-12 2006-09-05 Theravance, Inc. Calcium channel drugs and uses
US6255280B1 (en) * 1999-04-08 2001-07-03 University Of Kentucky Research Foundation Protection against traumatic brain injury
US6479498B1 (en) 1999-06-04 2002-11-12 Theravance, Inc. Sodium channel drugs and uses
SG83735A1 (en) * 1999-07-03 2001-10-16 Advanced Medicine Inc Novel local anesthetic compounds and uses
US6875759B1 (en) 1999-07-21 2005-04-05 Kadmus Pharmaceuticals Substituted guanidines and the use thereof
EP1267896A1 (de) * 2000-03-28 2003-01-02 Robert J. Delorenzo Hemmung eines neuen calcium-strom, der sich bildet in neuronen während verletzungen darin, verhütet neuronalen zelltod
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
MXPA02001323A (es) 2000-05-10 2004-07-16 Alliance Pharma Microgranulos con base fosfolipida para la liberacion de farmaco.
AU2001292276A1 (en) * 2000-09-27 2002-04-08 Toray Industries, Inc. Nitrogen-containing compounds and ccr3 inhibitors containing the same as the active ingredient
US7521479B2 (en) * 2001-04-16 2009-04-21 Panacea Pharmaceuticals, Inc. Methods of treating prion disease in mammals
CA2468958C (en) 2001-12-19 2012-07-03 Nektar Therapeutics Pulmonary delivery of aminoglycosides
WO2003101402A2 (en) * 2002-06-04 2003-12-11 Avicena Group, Inc. Methods of treating cognitive dysfunction by modulating brain energy metabolism
WO2004071433A2 (en) * 2003-02-11 2004-08-26 Scion Pharmaceuticals, Inc. Methods of treating disease
US7880001B2 (en) 2004-04-29 2011-02-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US8415354B2 (en) 2004-04-29 2013-04-09 Abbott Laboratories Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US20100222316A1 (en) 2004-04-29 2010-09-02 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US7279897B2 (en) * 2004-04-30 2007-10-09 E. I. Du Pont De Nemours And Company Scanning a band of frequencies using an array of high temperature superconductor sensors tuned to different frequencies
US8198331B2 (en) 2005-01-05 2012-06-12 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US7217838B2 (en) 2005-01-05 2007-05-15 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
KR101496206B1 (ko) 2005-01-05 2015-02-27 애브비 인코포레이티드 11-베타-하이드록시스테로이드 데하이드로게나제 타입 1 효소의 억제제로서의 아다만틸 유도체
US20090192198A1 (en) 2005-01-05 2009-07-30 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US20070031342A1 (en) * 2005-06-22 2007-02-08 Nektar Therapeutics Sustained release microparticles for pulmonary delivery
WO2007009462A2 (en) * 2005-07-15 2007-01-25 Region Hovedstaden V/Glostrup Hospital Treatment of migraine and headaches
US9296697B2 (en) * 2005-08-24 2016-03-29 Abbott Laboratories Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors
US7601751B2 (en) 2005-09-01 2009-10-13 Bristol-Myers Squibb Company Indole acetic acid acyl guanidines as β-secretase inhibitors
WO2007038169A2 (en) * 2005-09-23 2007-04-05 Nitto Denko Corporation Multi-valent guanidinium compounds for molecular translocation across cellular membranes and epithelial tissues
US7700565B2 (en) * 2005-09-23 2010-04-20 Nitto Denko Corporation Peptide nucleic acid based guanidinium compounds
WO2007038172A2 (en) * 2005-09-23 2007-04-05 Nitto Denko Corporation Guanidinium carriers
US7390925B2 (en) 2006-04-03 2008-06-24 Bristol-Myers Squibb Company Oxime-containing acyl guanidines as beta-secretase inhibitors
EP2468272A1 (de) * 2006-05-11 2012-06-27 Avicena Group, Inc. Verfahren zur Behandlung eines Nervenleidens mit Kreatinmonohydrat
JP5736098B2 (ja) 2007-08-21 2015-06-17 アッヴィ・インコーポレイテッド 中枢神経系障害を治療するための医薬組成物
US9233099B2 (en) 2012-01-11 2016-01-12 University Of Cincinnati Methods of treating cognitive dysfunction by modulating brain energy metabolism
DE102013216113A1 (de) 2013-08-14 2015-03-05 Homag Holzbearbeitungssysteme Gmbh Beschichtungsaggregat
US20180127358A1 (en) * 2015-01-28 2018-05-10 Kyushu University, National University Corporation Anti-inflammatory drug and uses thereof

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1730388A (en) * 1929-10-08 Winfield scott
US1677235A (en) * 1928-07-17 Balph v
US2145214A (en) * 1939-01-24 Parasiticide
US1422506A (en) * 1921-07-02 1922-07-11 Dovan Chemical Corp Process of making diphenylguanidine
US1642180A (en) * 1922-11-27 1927-09-13 Du Pont Di-para-xylylguanidine
US1597233A (en) * 1923-02-27 1926-08-24 Albert C Burrage Vulcanization of rubber
GB223410A (en) * 1923-11-01 1924-10-23 British Dyestuffs Corp Ltd Improvements in the manufacture of diarylguanidines
GB224376A (en) * 1923-11-01 1924-11-13 British Dyestuffs Corp Ltd Improvements in the manufacture of triarylguanidines
GB258203A (en) * 1925-09-23 1926-09-16 Silesia Ver Chemischer Fabrike An improved process for the production of symmetrical di-arylguanidines
US1672431A (en) * 1925-11-30 1928-06-05 Firm Chem Fab Auf Actien Vorma Symmetrical diarylized guanidine compounds
US1795398A (en) * 1925-12-21 1931-03-10 Huguenin Albert Elevator for boats with constant draft
US1850682A (en) * 1927-01-10 1932-03-22 Ig Farbenindustrie Ag Substituted guanidines
US1795738A (en) * 1927-09-12 1931-03-10 Scheringkahlbaum A G Method of producing substituted guanidines
DE514248C (de) * 1927-09-13 1930-12-10 Schering Kahlbaum Akt Ges Verfahren zur Darstellung substituierter Guanidine
US1756315A (en) * 1927-11-28 1930-04-29 Rubber Service Lab Co Rubber vulcanization process
US1915922A (en) * 1931-03-02 1933-06-27 American Cyanamid Co Mothproofing
GB478525A (en) * 1936-02-13 1938-01-20 Georg Knoth Process for the preparation of diphenylguanidine
GB475525A (en) * 1936-05-22 1937-11-22 Edward Dodson Improvements in or connected with cowling flaps for aircraft engines
US2254009A (en) * 1940-04-24 1941-08-26 American Cyanamid Co Symmetrical di-2-octyl-guanidine
US2283003A (en) * 1940-05-13 1942-05-12 C B Henschel Mfg Co Printing apparatus
US2274476A (en) * 1940-08-23 1942-02-24 American Cyanamid Co Insecticide and moth larvae repellent
US2362915A (en) * 1940-12-24 1944-11-14 Courtaulds Ltd Process for improving the fastness to washing of dyed cellulosic textile materials
US2289541A (en) * 1941-01-18 1942-07-14 American Cyanamid Co Insecticide
US2704710A (en) * 1950-04-18 1955-03-22 Gen Aniline & Film Corp Precipitation of azo dyes in silver halide emulsions by means of guanidine and biguanide compounds containing long alkyl chains
US2633474A (en) * 1951-07-21 1953-03-31 Monsanto Chemicals 1, 3-bis (o-ethylphenyl) guanidine
US3117994A (en) * 1959-12-03 1964-01-14 Monsanto Canada Ltd Nu, nu', nu'-trisubstituted guanidines
US3168562A (en) * 1959-12-23 1965-02-02 Burroughs Wellcome Co Substituted benzylguanidines
GB952194A (en) * 1960-12-23 1964-03-11 Smith Kline French Lab New guanidine derivatives and processes for preparing the same
US3140231A (en) * 1961-08-14 1964-07-07 Rohm & Haas T-octylguanidines as antihypertensive agents
US3159676A (en) * 1962-02-07 1964-12-01 Smith Kline French Lab Naphthyl containing guanidines
US3248426A (en) * 1962-03-01 1966-04-26 American Home Prod Nu-(1-naphthylmethyl)-guanidine and acid addition salt thereof
US3301755A (en) * 1962-04-18 1967-01-31 Ciba Geigy Corp Allylic guanidines
CH433246A (de) * 1962-06-25 1967-04-15 Ciba Geigy Verfahren zur Herstellung von Guanidinverbindungen
US3320229A (en) * 1963-08-26 1967-05-16 Stauffer Chemical Co Complexes of guanidines with completely halogenated acetones
US3479437A (en) * 1963-08-26 1969-11-18 Stauffer Chemical Co Guanidine complexes as fungicides
GB1110947A (en) * 1963-12-13 1968-04-24 Evans Medical Ltd Guanidines
US3228975A (en) * 1964-04-10 1966-01-11 American Cyanamid Co Akyl-substituted cyclohexyl guanidines and biguanides
NL125066C (de) * 1964-07-31
US3391189A (en) * 1966-01-13 1968-07-02 Ciba Geigy Corp Nu-allyl-guanidines and salts thereof
US3639477A (en) * 1968-06-17 1972-02-01 Parke Davis & Co Novel propoxyguanidine compounds and means of producing the same
US3803324A (en) * 1968-07-09 1974-04-09 Boehringer Mannheim Gmbh Amino-guanidine derivatives useful for regulating blood pressure
GB1208252A (en) * 1969-01-01 1970-10-14 American Cyanamid Co Use of alkylguanidine salts as viricides
US3547951A (en) * 1969-06-17 1970-12-15 Waldo R Hardie 1,3-dioxolan-4-yl-alkyl guanidines
AU1592270A (en) * 1969-06-17 1971-12-09 Imperial Chemical Industries Limited Antiviral processes and compositions
US3949089A (en) * 1969-06-23 1976-04-06 Burroughs Wellcome Co. Substituted guanidine compounds as antifibrillatory agents
US3975533A (en) * 1970-04-29 1976-08-17 Shell Oil Company Therapeutic agents
US4060640A (en) * 1970-04-29 1977-11-29 Shell Oil Company Therapeutic agents
US3968243A (en) * 1970-06-05 1976-07-06 Burroughs Wellcome Co. Substituted guanidine compounds in the treating of arrythmias
NL7011683A (de) * 1970-08-07 1972-02-09
US3908013A (en) * 1970-09-17 1975-09-23 Armour Pharma Pharmaceutical aromatic guanidine compositions and methods of using same
US3769427A (en) * 1970-10-01 1973-10-30 Armour Pharma Pharmaceutical compositions and methods of using same
US3681459A (en) * 1970-10-01 1972-08-01 Armour Pharma Guanidine compounds and use of same
US3976787A (en) * 1970-11-10 1976-08-24 Armour Pharmaceutical Company Pharmaceutical guanidine preparations and methods of using same
US3784643A (en) * 1970-12-11 1974-01-08 Colgate Palmolive Co Aryloxyalkylguanidines
DE2133056C3 (de) * 1971-07-02 1980-10-23 Vsesojuznyj Nautschno-Issledovatelskij Institut Chimitscheskich Sredstv Zaschtschity Rastenij, Moskau Verwendung von NJS-di-alkyl-N'arylsubstituierten Guanidinen zur Bekämpfung von Mehltaupilzen und Grauschimmel der Pflanzen
US3976643A (en) * 1973-07-13 1976-08-24 William H. Rorer, Inc. Guanidines
NL7315350A (nl) * 1973-11-09 1975-05-13 Akzo Nv Nieuwe aminoguanidine verbindingen.
US4007181A (en) * 1974-02-11 1977-02-08 The Upjohn Company Adamantyl containing guanidines
US4052455A (en) * 1974-04-08 1977-10-04 Mead Johnson & Company Styrylamidines
US4014934A (en) * 1974-04-15 1977-03-29 Armour Pharmaceutical Company Substituted 4'-hydroxyphenyl guanidines and methods of using the same
US4109014A (en) * 1974-10-29 1978-08-22 Armour Pharmaceutical Company Pharmaceutical, compositions containing substituted 4'-hydroxyphenyl guanidines and methods of using same
US4130663A (en) * 1975-08-04 1978-12-19 Mead Johnson & Company Styrylamidines
US4169154A (en) * 1976-04-15 1979-09-25 Hoffmann-La Roche Inc. Method of treating depression with thiourea derivatives
US4051256A (en) * 1976-09-19 1977-09-27 Imperial Chemical Industries Limited Guanidine derivatives
US4101659A (en) * 1977-08-29 1978-07-18 Mcneil Laboratories, Incorporated Benzhydryl guanidines
US4172204A (en) * 1977-10-07 1979-10-23 Syntex (U.S.A.) Inc. Method for preparing 4,5-dihydro-2-alkoxycarbonylamino-5-carbocyclic aryl imidazoles and intermediates thereof
PH17019A (en) * 1980-03-01 1984-05-11 Wyeth John & Brother Ltd 4-piperidyl-or dehydropiperidyl-urea derivatives and method of use
DE3108564A1 (de) * 1981-03-06 1982-11-18 Bayer Ag, 5090 Leverkusen N-tert-butyl-phenyl-n'-cyclohexyl-quanidine, verfahren zu ihrer herstellung sowie ihre verwendung als fungizide
US4393077A (en) * 1981-07-02 1983-07-12 William H. Rorer, Inc. 1-Methylene-1-phenylguanidine compounds
FR2509724B1 (fr) * 1981-07-15 1985-10-25 Centre Nat Rech Scient Nouvelles guanidines a fort encombrement sterique et procedes pour leur preparation
US4742054A (en) * 1982-11-23 1988-05-03 Naftchi Nosrat E Treatment of mammals suffering from damage to the central nervous system
US5130324A (en) * 1984-03-19 1992-07-14 The Rockefeller University 2-alkylidene-aminoguanidines and methods of use therefor
US4663263A (en) * 1984-10-19 1987-05-05 Canon Kabushiki Kaisha Toner, charge-imparting material and composition containing substituted guanidine compound for electrophotography
DE3501383A1 (de) * 1985-01-17 1986-07-17 Akzo Gmbh, 5600 Wuppertal Verfahren zur herstellung von n,n'-disubstituierten guanidinen
EP0259371B1 (de) * 1986-01-28 1992-05-13 JOHN WYETH &amp; BROTHER LIMITED Verfahren zur herstellung von 3-dimethylamino 7-methyl-1,2,4-benzotriazin und azapropazon
US5093525A (en) * 1986-07-10 1992-03-03 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists
US5190976A (en) * 1986-07-10 1993-03-02 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And University Of Oregon N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists
US5312840A (en) * 1986-07-10 1994-05-17 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education Substituted guanidines having high binding to the sigma receptor and the use thereof
US5385946A (en) * 1986-07-10 1995-01-31 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Method for treating hypertension with disubstituted granidine compounds
US4906779A (en) * 1986-07-10 1990-03-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists
US4709094A (en) * 1986-07-10 1987-11-24 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Sigma brain receptor ligands and their use
US4837218A (en) * 1987-10-23 1989-06-06 Washington University Alkylated bicycloalkaneamines for treatment of neurotoxic injury
US4891185A (en) * 1988-01-22 1990-01-02 Goldin Stanley M High resolution monitoring device
US5242947A (en) * 1988-02-10 1993-09-07 New York University Use of polyamines as ionic-channel regulating agents
ATE110265T1 (de) * 1989-05-02 1994-09-15 Oregon State Verwendung von sigma-rezeptor-liganden zur herstellung eines anxiolytikums.
US5262568A (en) * 1990-03-02 1993-11-16 State Of Oregon Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists
KR100353486B1 (ko) * 1990-03-02 2003-01-06 스테이트 오브 오레곤,액팅 바이 앤드 쓰로우 디 오레곤 스테이트 보드 오브 하이어 에주케이션,액팅포앤드 온 비해프 오브 디 오레곤 헬쓰 사이언시즈 유니버시티 앤드 더 유니버시티 오브 오레곤,유진,오레곤 삼치환및사치환된구아니딘류및이를함유하는약제조성물
US5336689A (en) * 1990-03-02 1994-08-09 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists
JPH05508836A (ja) * 1990-05-25 1993-12-09 オレゴン州 シグマ受容体に対して高い結合性を有する置換グアニジンおよびその使用
JPH06501002A (ja) * 1990-08-30 1994-01-27 オレゴン州 シグマ受容体に対して高い結合性を有する置換アミジン類およびその使用
AU670232B2 (en) * 1991-02-08 1996-07-11 Cambridge Neuroscience, Inc. Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers
US5298657A (en) * 1992-03-20 1994-03-29 Cambridge Neuroscience Inc. Preparation of substituted guanidines

Also Published As

Publication number Publication date
ZA92944B (en) 1993-08-10
DE69230220T2 (de) 2000-06-21
US5677348A (en) 1997-10-14
US5837737A (en) 1998-11-17
EP0940139A3 (de) 2000-01-19
US5652269A (en) 1997-07-29
ATE288262T1 (de) 2005-02-15
KR100246083B1 (ko) 2000-03-15
US6071969A (en) 2000-06-06
CA2099245A1 (en) 1992-08-09
AU1449692A (en) 1992-09-15
JPH06506455A (ja) 1994-07-21
US5403861A (en) 1995-04-04
DE69233479T2 (de) 2006-03-16
US5637623A (en) 1997-06-10
EP0584088B1 (de) 1999-10-27
AU709863B2 (en) 1999-09-09
ATE186047T1 (de) 1999-11-15
US5670519A (en) 1997-09-23
IE20030530A1 (en) 2003-10-01
IE920441A1 (en) 1992-08-12
US5614630A (en) 1997-03-25
US5672608A (en) 1997-09-30
EP0940139B1 (de) 2005-02-02
DE69233479D1 (de) 2005-03-10
WO1992014697A1 (en) 1992-09-03
AU6813096A (en) 1997-01-09
PT100115A (pt) 1993-06-30
US5622968A (en) 1997-04-22
EP0940139A2 (de) 1999-09-08
US5681861A (en) 1997-10-28
US5686495A (en) 1997-11-11
PT100115B (pt) 1999-06-30
EP0584088A1 (de) 1994-03-02
AU670232B2 (en) 1996-07-11
EP0584088A4 (de) 1995-01-18

Similar Documents

Publication Publication Date Title
DE69230220D1 (de) Substituierte guanidine und derivate hiervon als modulatoren der freisetzung von neurotransmittern und neue methode zur identifizierung von inhibitoren der neurotransmitter-freisetzung
ES2100907T3 (es) Bencimidazoles, medicamentos que contienen estos compuestos y proced imiento para su preparacion.
DE69017606T2 (de) Substituierte Cyclohexanole mit zentraler Nervensystemwirkung.
ATE236115T1 (de) Dimer-selektive rxr modulatoren und verfahren zu ihrer verwendung
DE69128516T2 (de) Neue Mercaptoacetylamid-Derivate zur Verwendung als Enkephalinase- und ACE-Hemmer
DE68927697T2 (de) Fluor substituierte Benzocycloheptapyridine, Zusammensetzungen und Verfahren zur Verwendung derselben als antihistaminische Verbindungen
ID26033A (id) Metode penstabilan komposisi bahan farmasi dengan penggunaan khusus dari antioksidan
ATE170508T1 (de) Bisulfit-additionsverbindungen von argininaldehyden und ihre verwendung als thrombininhibitoren und antikoagulantien
ATE120738T1 (de) 2,4-diamino-pyrimidin-3-oxid-derivate und deren verwendung bei der behandlung und zur verhütung von haarfall.
DE69232883T2 (de) Substituierte heterocyklische derivate, verwendbar als plättchenaggregationshemmstoffe
BR0015416A (pt) Composições contendo derivados do ácido hidroxieicosa tetraenóico e métodos de uso no tratamento de distúrbios de olhos secos
DK0556329T3 (da) Substituerede piperaziner som midler til behandling af centralnervesystemet
DE69528710D1 (de) 2-substituierte 1,2,5-thiadiazolidin-3-on-1,1-dioxiden, zusammensetzung und deren verwendung
ATE288894T1 (de) Aromatische maleimide und ihre verwendung als photoinitiatoren
DK490486D0 (da) Sammensaetning til behandling af atherosclerose, tromboser og/eller perifere karsygdomme
DE69535131D1 (de) Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems
FI943499A0 (fi) Happokorvikkeita sisältäviä tetrahydro-1H-bentsatsepinoneja
DE69419640D1 (de) Pharmakologische Verwendung von 5-Aminophthaloylhydrazide; ihre Zusammensetzung und Anwendung
DE69510729D1 (de) Suspensionskonzentrat von insektiziden und akariziden Arylpyrrolen
NO930205L (no) Benzimidazoler, legemidler inneholdende disse, og fremgangsmaate for deres fremstilling
DE69806465D1 (de) Eine heteroethynylen-brücke enthaltende bi-aromatische verbindungen und diese enthaltende pharmazeutische und kosmetische zusammensetzungen
ATE397663T1 (de) Humane ltrpc7 proteine, dafür kodierende nukleinsäuren und deren verwendungen
BR0313432A (pt) Uso terapêutico de aminoácidos bicìclicos ou tricìclicos fundidos
ID27964A (id) Turuna-azabisikloheptana n-tersubstitusi, pembuatan dan penggunaannya

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee